Worsening respiratory functions can significantly influence the choice of antihypertensive medication. A recently published study explored whether angiotensin-converting enzyme inhibitors (ACEi) can worsen lung function and whether this effect also appears with angiotensin II receptor blockers (ARBs, i.e., sartans). These findings are crucial for clinical practice, especially in treating patients at high risk for respiratory adverse effects.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
